Paolo Tralongo
Research Subjects
Paolo Tralongo has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
- Antonella Surbone
New York University Medical School
2 shared publications - Andrea Pace
Neuro-Oncology Unit, IRCCS-Regina Elena National Cancer Institute, Rome, Italy
1 shared publication - Antonino Carmelo Tralongo
Department of Clinical Oncology, Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy
1 shared publication - Armando Santoro
Istituto di Ricovero e Cura a Carattere Scientifico Humanitas Research Hospital, Rozzano (Milan), Italy
1 shared publication - Augusto Caraceni
Palliative Care, Pain Therapy and Rehabilitation Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
1 shared publication - Diego Serraino
Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, 33081 Aviano, Italy
1 shared publication
Latest Publications
- 7 October 2021
- Published by Springer Nature
- p. 417-424
Patients Categorization
- 22 August 2019
- Published by Wiley in European Journal of Cancer Care
- Vol. 28 (6) , e13139
Major patterns of cancer cure: Clinical implications
Introduction This review aimed to classify major patterns of cancer cure and discuss clinical implications. Patterns of cancer cure were identified, in terms of long‐term survival and life expectancy, by means of two recently estimated indicators: cure fraction (CF) and time to cure (TTC). Methods We considered population‐based studies reporting results for some cancer types on CF, defined as the proportion of patients who will reach the same life expectancy of the general population, or/and TTC, the time span necessary to experience a negligible excess mortality. TTC is obtained using conditional relative survival, which indicates the probability of surviving an additional y number of years, given that patients already survived x number of years. Results Four major patterns of cancer types emerged from published studies: (a) cancers with a CF > 60% and a TTC < 5 years (e.g., testicular, thyroid); (b) cancers with a CF between 20% and 50% and a TTC < 10 years (colon, rectum); (c) cancers showing a CF of approximately 50% and TTC > 10 years (breast, prostate and bladder); (d) cancers with a CF < 20% and uncertain TTC (lung or pancreas). Conclusion Clinical and social impact of “cancer cure” categorisation are discussed in details. Recognising a cancer patient as cured represents an opportunity to improve their quality of life.
- 22 August 2019
- Published by Wiley in European Journal of Cancer Care
- Vol. 28 (6) , e13139
Major patterns of cancer cure: Clinical implications
Introduction This review aimed to classify major patterns of cancer cure and discuss clinical implications. Patterns of cancer cure were identified, in terms of long‐term survival and life expectancy, by means of two recently estimated indicators: cure fraction (CF) and time to cure (TTC). Methods We considered population‐based studies reporting results for some cancer types on CF, defined as the proportion of patients who will reach the same life expectancy of the general population, or/and TTC, the time span necessary to experience a negligible excess mortality. TTC is obtained using conditional relative survival, which indicates the probability of surviving an additional y number of years, given that patients already survived x number of years. Results Four major patterns of cancer types emerged from published studies: (a) cancers with a CF > 60% and a TTC < 5 years (e.g., testicular, thyroid); (b) cancers with a CF between 20% and 50% and a TTC < 10 years (colon, rectum); (c) cancers showing a CF of approximately 50% and TTC > 10 years (breast, prostate and bladder); (d) cancers with a CF < 20% and uncertain TTC (lung or pancreas). Conclusion Clinical and social impact of “cancer cure” categorisation are discussed in details. Recognising a cancer patient as cured represents an opportunity to improve their quality of life.